# Antimicrobial Resistance and Associated Risk Factors for Clostridium difficile in Patients Attending Tertiary Care Settings

**Authors:** Murad A. Mubaraki, Mubbashir Hussain, Faaiz Ul Hassan, Shahzad Munir, Fozia Fozia, Ijaz Ahmad, Fatima Bibi, Samia Sultan, Ziaullah Zialluh

PMC · DOI: 10.1155/2024/6613120 · Journal of Tropical Medicine · 2024-05-16

## TL;DR

This study found high rates of antimicrobial resistance in Clostridium difficile in Pakistan, linked to factors like age, antibiotic use, and surgeries.

## Contribution

The study provides new insights into C. difficile resistance patterns and risk factors in a Pakistani tertiary care setting.

## Key findings

- 24% of stool samples tested positive for C. difficile, with high resistance to multiple antibiotics.
- Resistance was highest to penicillin and amoxicillin, lowest to vancomycin and imipenem.
- CDI was significantly associated with age, antibiotic use, surgeries, and comorbidities.

## Abstract

To determine the incidence of antimicrobial-resistant emerging pathogens, Clostridium difficile, and its associated risk factors in tertiary care setups of Pakistan. This cross-sectional prospective study was conducted from January 2019 to December 2020, to determine the prevalence and antimicrobial resistance patterns of C. difficile strains isolated from 450 stool specimens of patients suffering from diarrhea hospitalized in tertiary care hospitals in Peshawar, Pakistan. The stool samples of the patients were processed for culture and detection of toxin A and toxin B by enzyme-linked immunosorbent assay (ELISA) and tpi PCR. The drug sensitivity test was performed for antibiotics including ampicillin, cefixime, cefepime, amoxicillin, nalidixic acid, sulpha/TMP (SXT), chloramphenicol, metronidazole, vancomycin, ciprofloxacin, levofloxacin, and imipenem. Of 450 stool specimens, 108 (24%) were positive for C. difficile by stool culture, whereas 115 (25.5%) were only positive for C. difficile toxins based on ELISA and PCR (128 (28.6%). Of 108, 90.7% (n = 98) isolates were resistant to one antibiotic, and 90 (83.4%) were resistant to three or more antimicrobials. The highest resistance rates were found against penicillin (83.3%) followed by amoxicillin (70%), nalidixic acid (61%), and metronidazole (38%), and the lowest resistance was found against vancomycin (6.4%) and imipenem (3.7%). CDI was statistically significantly correlated with increased age, use of antibiotics, abdominal surgeries, use of proton pump inhibitors and H2a, and presence of comorbidities. The high frequency of C. difficile in Peshawar, Pakistan, indicates that CDI is an important nosocomial infection in different hospitals. The results will be helpful for clinicians to redesign control and therapeutic strategies in hospitals.

## Linked entities

- **Chemicals:** ampicillin (PubChem CID 6249), cefixime (PubChem CID 5362065), cefepime (PubChem CID 5479537), amoxicillin (PubChem CID 33613), nalidixic acid (PubChem CID 4421), chloramphenicol (PubChem CID 5959), metronidazole (PubChem CID 4173), vancomycin (PubChem CID 14969), ciprofloxacin (PubChem CID 2764), levofloxacin (PubChem CID 149096), imipenem (PubChem CID 104838)
- **Diseases:** diarrhea (MONDO:0001673)

## Full-text entities

- **Diseases:** Clostridium difficile (MESH:D003015), diarrhea (MESH:D003967), CDI (MESH:D020790), nosocomial infection (MESH:D003428)
- **Chemicals:** penicillin (MESH:D010406), vancomycin (MESH:D014640), imipenem (MESH:D015378), ciprofloxacin (MESH:D002939), chloramphenicol (MESH:D002701), ampicillin (MESH:D000667), metronidazole (MESH:D008795), cefepime (MESH:D000077723), levofloxacin (MESH:D064704), nalidixic acid (MESH:D009268), cefixime (MESH:D020682), amoxicillin (MESH:D000658), SXT (-)
- **Species:** Clostridioides difficile (species) [taxon 1496], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11115991/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11115991/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC11115991/full.md

---
Source: https://tomesphere.com/paper/PMC11115991